Isotretinoin exposure may not increase IBD risk in patients
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
The evidence on the risk of inflammatory bowel disease (IBD) among patients with acne vulgaris (AV) exposed to isotretinoin is controversial. In order to compare the risk of IBD in isotretinoin-exposed and unexposed AV patients, a study was performed.

Retrospective cohort analysis of patients with AV with and without isotretinoin exposure was identified using electronic health records. Primary outcomes were 6-month and 1-year IBD incidence.

Results:
-The crude 6-month IBD incidence was 0.08% (21/27,230) among isotretinoin-exposed patients with AV compared to 0.04% (254/631,089) among those unexposed.
-The crude 1-year IBD incidence was 0.10% (28/27,230) among isotretinoin exposed patients with AV and 0.08% (477/631,089) among those unexposed.
-The odds of developing IBD within 6 months were 87% higher among isotretinoin-exposed patients with AV compared to those unexposed, although the absolute difference was small (risk difference, 2.6 more cases per 10,000 patients).
-There was no significant difference in the odds of developing IBD at 1 year between isotretinoin-exposed and unexposed patients with AV (adjusted odds ratio, 1.40).

Through studies it was concluded that IBD incidence among isotretinoin-exposed patients with AV is very low, and the risk appears similar to that for unexposed patients with AV.

Source: https://www.jaad.org/article/S0190-9622(20)32211-8/fulltext
Like
Comment
Share